Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astex Therapeutics has received FDA approval of its investigational new drug application for AT13387, a selective small molecule inhibitor of Hsp90 to treat cancer.
Subscribe to our email newsletter
This is the third IND candidate from Astex’s internal discovery and development programmes to be approved. Astex plans to begin clinical trials of AT13387 in cancer patients during 2008.
Harren Jhoti, CEO of Astex, said: “This approval is a great achievement and a testament to the productivity of our fragment-based drug discovery platform and keeps us on target to deliver at least one IND candidate per year.”